Sunday, December 14, 2025

Latest

Microsoft: Earnings Estimates For Q1 2022

Microsoft (NASDAQ: MSFT) will be reporting its first quarter financial results on the 26th after the markets close. Analysts have a consensus $339.26 12-month price target on the company, via a total of 41 analysts, with 17 analysts having strong buy ratings. 22 analysts meanwhile have buy ratings, and 2 analysts have hold ratings on the company. The street high sits at a $384 price target, and the lowest target sits at $281.78.

25 analysts have revenue estimates for the first quarter. The mean revenue estimate between all 25 analysts is $44.97 billion; this number has been revised upwards from $41.90 billion at the start of April. The highest revenue estimate is $44.77 billion, while the lowest is $43.66 billion.

Onto EBITDA estimates, there are currently 4 analysts who have first-quarter EBITDA estimates. The mean is currently $22.28 billion, with this number having been revised upwards from $20.35 billion at the start of April. The street high estimate currently sits at $22.76 billion in EBITDA and the lowest is $21.56 billion.

Analysts estimate that quarterly earnings per share will come in at $2.07, with this number being revised upwards from $1.90 at the start of April. Street high is $2.17 and the lowest estimate is $2.03 per share for the quarter.


Information for this briefing was found via Edgar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why Canada Has So Few Projects That Can Be Built Before 2030 | Dan Wilton – First Mining

Guanajuato Silver: Q3 Results Overshadowed By Silver Ripping

I Went to See the Highest Grade Silver on Earth | Nord Precious Metals

Recommended

Steadright Locks Up Goundafa Polymetallic Mine Under Binding MOU

Emerita Resources Awards Contract For Pre-Feasibility Study On Iberian Belt West Project

Related News

Medipharm Labs Receives Price Target Reduction From Canaccord To $1.75

Yesterday, On November 16th, Medipharm Labs (TSX: LABS) reported their third quarter financial results. Reported...

Tuesday, November 17, 2020, 03:37:00 PM

Farmers Edge: Canaccord, National Bank Initiate With $25 Price Target

Early this month Farmers Edge inc (TSX: FDGE) completed their $125 million IPO on the...

Friday, March 26, 2021, 11:41:00 AM

Haywood Cuts Cresco Labs Price Target To $15.50 On Poor Earnings

At the tail end of March, Cresco Labs (CSE: CL) announced its fourth-quarter financial results,...

Sunday, April 3, 2022, 03:09:00 PM

Antibe Therapeutics: Canaccord Initiates Coverage, Issues $1.50 Price Target

Recently, Canaccord Genuity’s Tania Gonsalves initiated coverage on Antibe Therapeutics (TSXV: ATE), a biotechnology company...

Tuesday, August 18, 2020, 01:46:28 PM

Canaccord: 2020 To Be Transition Year For Medipharm Labs

Last week, Medipharm Labs (TSX: LABS) reported their second-quarter earnings. Revenue came in at $13.9...

Saturday, August 22, 2020, 01:38:00 PM